Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Innate Pharma    IPH   FR0010331421

INNATE PHARMA

(IPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Innate Pharma S.A. and Encourages Investors with Losses to Contact the Firm

share with twitter share with LinkedIn share with facebook
share via e-mail
01/29/2020 | 08:02pm EDT

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Innate Pharma S.A. (“Innate” or “the Company”) (NASDAQ: IPHA) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Innate announced on January 9, 2020, that it would “suspend enrollment of new patients” in the TELLOMAK Phase II trial of lacutamab (IPH4102). The trial was designed to evaluate the efficacy and safety of lacutamab in patients with advanced T-cell lymphomas. The Company’s decision was based on “ongoing discussions with regulatory authorities regarding Good Manufacturing Practice (GMP) deficiencies at the Company’s manufacturing subcontractor site that manages the fill and finish operations of the lacutamab clinical vials.” Based on this news, shares of Innate fell by nearly 10% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.


© Business Wire 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on INNATE PHARMA
03/10INNATE PHARMA : First patient dosed in IPH5201 Phase I clinical trial in advance..
AQ
03/10INNATE PHARMA : reports full year 2019 financial results and business update
GL
03/10First Patient Dosed in IPH5201 Phase I Clinical Trial in Advanced Solid Tumor..
GL
03/10INNATE PHARMA : Slide show results
CO
03/10INNATE PHARMA : Annual results
CO
01/31INVESTIGATION REMINDER : The Schall Law Firm Announces it is Investigating Claim..
BU
01/29INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims A..
BU
01/29Rosen Law Firm Announces Investigation of Securities Claims Against Innate Ph..
BU
01/14INNATE PHARMA : SA - French regulatory agency agrees lacutamab TELLOMAK trial ca..
AQ
01/13INNATE PHARMA : French regulatory agency agrees lacutamab TELLOMAK trial can res..
GL
More news
Financials (EUR)
Sales 2019 90,6 M
EBIT 2019 -16,3 M
Net income 2019 -9,95 M
Finance 2019 49,3 M
Yield 2019 -
P/E ratio 2019 -39,8x
P/E ratio 2020 -110x
EV / Sales2019 4,24x
EV / Sales2020 2,87x
Capitalization 434 M
Chart INNATE PHARMA
Duration : Period :
Innate Pharma Technical Analysis Chart | IPH | FR0010331421 | MarketScreener
Technical analysis trends INNATE PHARMA
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 11,92  €
Last Close Price 5,50  €
Spread / Highest target 184%
Spread / Average Target 117%
Spread / Lowest Target 63,6%
EPS Revisions
Managers
NameTitle
Mondher Mahjoubi Chairman-Executive Board & Chief Executive Officer
Hervé Brailly Chairman-Supervisory Board
Laure-Hélène Mercier CFO & Member-Executive Board
Eric Vivier Chief Scientific Officer & Senior Vice President
Pierre F. Dodion Chief Medical Officer & Executive VP
Sector and Competitors